DYRK1B and melanoma: In a study [80] aiming to develop potent Dyrk1B inhibitors for combined treatment with MEK inhibitors AZD6244 or AZD8330 in melanoma tumors, a set of potent, selective, and cellular active Dyrk1B inhibitors was developed through a combination of targeted screening and structure-based design, as synthetic derivatives of azaindole (compound 2).